Samsung Medison Co., Ltd. appears in FDA records as the applicant on two substantially equivalent 510(k) decisions issued in the second half of 2026, both for diagnostic ultrasound systems classified under product code IYN and regulation 892.1550. The filings describe multi-model system families rather than single devices, and both were reviewed by a third party within the Radiology panel. The company's documented footprint in these sources is regulatory: applicant identity, device names, product codes and decision dates. [1][2][8]
The V10 and HERA Z10 clearance
K263150 was received on September 8, 2026 and decided on October 8, 2026 as substantially equivalent. The device name lists V10, cV10, H10, XV10 and XH10 Diagnostic Ultrasound Systems, each also in a ONE variant, plus the HERA Z10 Diagnostic Ultrasound System. The applicant is recorded as Samsung Medison Co., Ltd. of Hongcheon-Gun, Korea, with a Traditional clearance type, third-party review and a summary statement. [1][3][8]
A Samsung newsroom release dated September 7, 2026 announced the HERA Z10 as a premium obstetrics and gynecology ultrasound system, positioned alongside the flagship HERA Z20 to complete the HERA Z Series lineup. The release attributes AI-driven workflow claims to Samsung Medison; those figures are the publisher's statements, not FDA findings. [5]
The EVO X series clearance
K263182 was received on September 11, 2026 and decided on September 25, 2026 as substantially equivalent, also Traditional, third-party reviewed and in the Radiology panel. Its device name covers EVO X30, X20 and X10; EVO XP30, XP20 and XP10; and EVO XC30, XC20 and XC10 Diagnostic Ultrasound Systems, all under product code IYN and regulation 892.1550. [2][4][9]
Filing scope and classification
Both clearances sit under the classification name System, Imaging, Pulsed Doppler, Ultrasonic, a Class 2 category with regulation number 892.1550. The FDA pages for K263150 and K263182 list subsequent product codes ITX, IYO and LLZ, and both records state that no predetermined change control plan was authorized and that the submissions were not combination products. [3][4]
The supplied collection holds two linked 510(k) records, both with a substantially equivalent decision, and the smaller record sample of two entries carries the same decision count. These figures describe the supplied filings as of the snapshot date and are not measures of total company sales, total portfolio or safety performance. [1][2]
Applicant identity and related records
FDA.report lists a registration for SAMSUNG MEDISON CO., LTD. at 3366, Hanseo-ro, Nam-myeon, Hongcheon-Gun, Gangwon, with an expiration year of 2027, and indexes device listings including cV4 and cV5 Diagnostic Ultrasound Systems dated 2025-09-03. A filing address is a regulatory contact location and is not treated here as a corporate headquarters. [7]
An Innolitics page for K263150 references an earlier Samsung ultrasound clearance, K261412, covering V6, V7 and V8 family models. That reference appears in a related-records context; the present profile's dated filing examples are limited to K263150 and K263182. No parent company, brand ownership, customer base or commercial availability is verified in these sources. [6]




